6th Annual

Inflammation Inhibitors

Small Molecule and Macrocyclic Approaches

April 21-22, 2015  

 
 

Speakers were great and presented valuable data. Comprehensive conference and
overview of most current inflammation targets and therapies.

Tina T., Associate Scientist, Biogen Idec

Inflammation is a component of many chronic diseases or conditions whose prevalence, as the population ages, is increasing. Hence there is great interest in developing oral medications similar in their convenience to the current standard option of non-steroidal anti-inflammatory drugs (NSAIDS) and Cox2 inhibitors but with safer profiles for long-term use. Immunotherapies based on therapeutic antibodies have met with much success in the past decade by combating the immunological underpinnings of inflammation. However because of biologics’ less convenient formulation and expense, the spotlight is back on smaller molecules that have oral bioavailability potential and can be produced by organic chemistry approaches. The recent FDA approval of a small molecule JAK kinase inhibitor to fight inflammation, has also contributed to the excitement over small molecule approaches for anti-inflammatories.

In its sixth year, Cambridge Healthtech Institute’s Inflammation Inhibitors meeting will continue to feature medicinal chemistry-focused case studies of small molecule drug candidates progressing in pre-clinical and clinical development. New this year, larger synthetic small molecules such as macrocyclic peptides that have biovailability potential, will also be covered; a few such compounds have recently entered the clinic for inflammation conditions. In addition to featuring the kinase inhibitors progressing in drug development, drug leads directed against non-kinase and newer targets will be a part of the meeting. Join fellow drug discovery scientists for this day-and-a-half meeting that is in the first half of CHI's larger Drug Discovery Chemistry event.

Preliminary Agenda


NEW APPROACHES FOR CHRONIC INFLAMMATION

Retrospective Analysis of Phenotypic v. Target-Driven Drug Discovery

Jörg Eder, Ph.D., Executive Director, Novartis Institutes for BioMedical Research

New Targets Emerging from Genetics: Time to Look Back, Move Forward with Phosphatases? (PTPN22)

Nunzio Bottini, M.D., Ph.D., Associate Professor, Division of Cell Biology, La Jolla Institute for Allergy and Immunology

The Discovery of APD334, a Selective S1P1 Functional Antagonist

Robert Jones, Ph.D., Senior Director, Medicinal Chemistry, Arena Pharmaceuticals

A CUL4CRBN E3 Ubiquitin Ligase Modulator for Combating Autoimmune Disease

Ying Ye, Ph.D., Director, Clinical Pharmacology, Translational Development, Celgene


TARGETING INNATE IMMUNITY

Identification of RORc Inverse Agonists with Favorable in vivo PK and in vivo Suppression of IL-17

Benjamin Fauber, Ph.D., Scientist, Small Molecule Drug Discovery, Genentech

Novel Small Molecule Immunomodulators that Target Toll-Like Receptors

Hang Hubert Yin, Ph.D., Associate Professor, Chemistry and Biochemistry & BioFrontiers Institute, University of Colorado


KINASE INFLAMMATION TARGETS

Discovery of a New Series of Small Molecule Bruton’s Tyrosine Kinase Inhibitors

Mark Sabat, Ph.D., Principal Scientist, Medicinal Chemistry, Takeda

Development of a Bruton’s Tyrosine Kinase Inhibitor, ONO-4059: Potential Treatment for Rheumatoid Arthritis & Systemic Lupus Erythematosus

Yuko Ariza, Ph.D., Associate Project Leader, Exploratory Research Laboratories II, Ono Pharmaceutical Co.

PPIP5K 1 and 2: A New Class of Small Molecule Kinases for Anti-Inflammatory Drug Development

Steve Shears, Ph.D., Senior Investigator, Signal Transduction, NIH



For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (914) 723-0251
Email: ashah@healthtech.com 

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: cbenton@healthtech.com